Dr. Robert Galvin is the Chief Executive Officer of Equity Healthcare (EH), which oversees the management of health care for firms owned by private equity companies. EH’s focus is on using purchasing power to create innovative ways to achieve higher value health care through improved population health, clinical quality, and delivery system reforms. Currently, EH encompasses 50 companies with health care spending exceeding $1.5 billion annually. It is a wholly owned subsidiary of the Blackstone Group, where Dr. Galvin is an Operating Partner.


Previously, Dr. Galvin was Executive Director of Health Services and Chief Medical Officer for General Electric (GE) for 15 years, where he was in charge of the design and financial and clinical performance of GE’s health programs globally. He was also responsible for health policy strategies affecting employees. Dr. Galvin is a nationally recognized leader in the areas of market-based health policy and financing, quality measurement, and payment reform. His work has been published in the Harvard Business Review, New England Journal of Medicine, JAMA, and Health Affairs. Dr. Galvin was a co-founder of the Leapfrog Group and founder of two other groups, Bridges to Excellence/PROMETHEUS Payment and Catalyst for Payment Reform (CPR), all innovative endeavors that have helped drive the quality agenda.


Dr. Galvin is a member of the Institute of Medicine (IOM), a branch of the National Academy of Sciences. He is Chairman of the Board of CPR and is a board member of Real Endpoints, a privately held Informatics & Solutions company. Dr. Galvin is Professor Adjunct of Medicine and Health Policy at Yale University. He has received awards for his work from the National Business Group on Health, Healthcare Financial Management Association, and National Coalition for Cancer Survivorship. He is a fellow of the American College of Physicians.


Recent Posts by Robert Galvin

Can Employers Take A Bigger Role In Controlling Drug Costs?

Employees and employers alike continue to suffer from ‘sticker shock’ for prices for new drugs. While considerable attention has been paid to potential actions by Medicare or the FDA, there has been less focus on the role of private payers to solve the issue.

The Payment Reform Landscape: Tailoring Payment Reforms To Local Market Dynamics

Payment reform is rapidly expanding across the nation. However, while a one-size-fits-all model may work in certain markets, it’s unlikely to work in others. CPR pioneered a market assessment tool to provide stakeholders with a way to navigate how their market's characteristics impact options...

Payment Reform: A Promising Beginning, But Less Talk And More Action Is Needed

In the late 1990’s, smarting from the collapse of managed care, HCFA’s retreat from the public release of provider performance data, and continued large increases in health costs in the face of evidence of waste and variation in quality, a group of large employers established the so-called...

Provider Consolidation And Health Spending: Responding To A Growing Problem

As the country faces the fiscal cliff and continued deficit challenges, controlling health care expenditures will require aggressive efforts. When we look at why costs are rising and what the remedies are, we need to examine carefully a growing and under-publicized phenomenon: provider...